Background: We report on the 12-month safety and efficacy outcomes of a new non-valved glaucoma drainage device, the eyePlate-300 (Rheon Medical, Lausanne, Switzerland), in managing refractory glaucoma. Methods: A retrospective review was conducted on consecutive patients over 18 who underwent glaucoma drainage device (GDD) surgery with the eyePlate-300 after a single glaucoma consultation between February 2020 and April 2021, with at least 12 months of documented post-op follow-up. Results: A total of 16 eyes from 15 patients were included. Complete success was observed in 47% of patients and overall success in 83%. The mean IOP decreased from 31.5 mm Hg to 10.7 mm Hg (67% reduction from baseline), and the number of IOP-lowering drops was reduced from 3.1 to 0.7 at one year. The mean BCVA remained stable. No additional IOP-lowering surgeries were required, and no severe sight-threatening complications were noted. Conclusions: The initial one-year results suggest that the eyePlate could be a safe and effective device for reducing IOP in an ethnically diverse refractory glaucoma population. Further follow-up is necessary to determine the long-term safety and efficacy.

Purpose: This study aimed to describe the correlation of demographic and clinical factors with the Graves’ ophthalmopathy–quality of life (GO-QOL) visual function (VF) and appearance (A) scores in a cohort attending a metropolitan multidisciplinary thyroid eye disease (TED) service. Methods: This is a cross-sectional retrospective study of 152 consecutive TED patients who completed the GO-QOL questionnaire. Clinical parameters, including endocrine diagnosis and status, TED activity and severity, Gorman diplopia score, and TED treatments were recorded at the time of completing each questionnaire and retrospectively analyzed. Results: A total of 257 GO-QOL questionnaires were completed over 32 months, with 59 patients providing sequential responses. The mean age was 50.0 ± 13.1 years, 77.0% (117/152) were female and 52.0% (79/152) were Caucasian. Graves’ disease was present in 86.2% (131/152) of participants, and 91.4% (139/152) were euthyroid at the time of the questionnaire. The mean time since TED onset was 2.5 years (range: 0.25–180 months). The mean ± standard deviation GO-QOL scores in the mild, moderate-to-severe, and sight-threatening disease cohorts for VF were 92.2 ± 15.2, 70.9 ± 28.6, and 56.6 ± 29.6, respectively, and for A were 79.1 ± 22.3, 48.2 ± 29.7, and 66.1 ± 35.3, respectively. VF and A scores were inversely correlated with clinical activity scores. Both scores improved postimmunosuppression but only A scores improved following decompression and rehabilitation surgery. Females and younger patients had lower A but not VF scores. East Asians and Caucasians had higher VF and A scores than African-Caribbeans. Conclusion: The GO-QOL’s granularity highlights the diverse functional and psychosocial experiences of TED patients, underscoring the need to integrate this valuable but underutilized tool into routine clinical practice.